Silence Therapeutics (SLN) Accounts Payables: 2019-2025
Historic Accounts Payables for Silence Therapeutics (SLN) over the last 1 years, with Sep 2025 value amounting to $17.0 million.
- Silence Therapeutics' Accounts Payables was N/A to $17.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.0 million, marking a year-over-year change of. This contributed to the annual value of $16.4 million for FY2024, which is 5.55% up from last year.
- Silence Therapeutics' Accounts Payables amounted to $17.0 million in Q3 2025, which was up 18.74% from $14.3 million recorded in Q2 2025.
- In the past 5 years, Silence Therapeutics' Accounts Payables ranged from a high of $18.8 million in Q1 2025 and a low of $14.3 million during Q2 2025.
- Its 3-year average for Accounts Payables is $16.4 million, with a median of $16.4 million in 2024.
- Data for Silence Therapeutics' Accounts Payables shows a peak YoY spiked of 34.38% (in 2021) over the last 5 years.
- Silence Therapeutics' Accounts Payables (Quarterly) stood at $14.5 million in 2021, then rose by 1.94% to $14.8 million in 2022, then rose by 4.86% to $15.5 million in 2023, then increased by 5.55% to $16.4 million in 2024, then reached $17.0 million in 2025.
- Its Accounts Payables stands at $17.0 million for Q3 2025, versus $14.3 million for Q2 2025 and $18.8 million for Q1 2025.